Business Description
TheraCryf PLC
ISIN : GB00BSVYN304
Description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.77 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -13.54 | |||||
Beneish M-Score | 8.01 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.8 | |||||
3-Year EPS without NRI Growth Rate | 15.1 | |||||
3-Year FCF Growth Rate | 18.1 | |||||
3-Year Book Growth Rate | -40.6 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.06 | |||||
9-Day RSI | 40.01 | |||||
14-Day RSI | 38.83 | |||||
6-1 Month Momentum % | -21.43 | |||||
12-1 Month Momentum % | -67 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.19 | |||||
Quick Ratio | 4.19 | |||||
Cash Ratio | 2.77 | |||||
Days Sales Outstanding | 427.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -898.99 | |||||
Net Margin % | -792.17 | |||||
FCF Margin % | -756.57 | |||||
ROE % | -81.01 | |||||
ROA % | -69.27 | |||||
ROIC % | -590.15 | |||||
ROC (Joel Greenblatt) % | -1028.9 | |||||
ROCE % | -91.95 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7 | |||||
PB Ratio | 0.78 | |||||
Price-to-Tangible-Book | 0.7 | |||||
EV-to-EBIT | -0.28 | |||||
EV-to-Forward-EBIT | -0.71 | |||||
EV-to-EBITDA | -0.28 | |||||
EV-to-Forward-EBITDA | -0.76 | |||||
EV-to-Revenue | 2.49 | |||||
EV-to-Forward-Revenue | 2.36 | |||||
EV-to-FCF | -0.33 | |||||
Price-to-Net-Current-Asset-Value | 0.7 | |||||
Earnings Yield (Greenblatt) % | -357.14 | |||||
FCF Yield % | -100.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TheraCryf PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | 0.396 | ||
EPS (TTM) (£) | -0.011 | ||
Beta | 1.79 | ||
Volatility % | 44.3 | ||
14-Day RSI | 38.83 | ||
14-Day ATR (£) | 0.000619 | ||
20-Day SMA (£) | 0.007108 | ||
12-1 Month Momentum % | -67 | ||
52-Week Range (£) | 0.0059 - 0.0252 | ||
Shares Outstanding (Mil) | 427.35 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TheraCryf PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TheraCryf PLC Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
TheraCryf PLC Frequently Asked Questions
What is TheraCryf PLC(LSE:TCF)'s stock price today?
The current price of LSE:TCF is £0.01. The 52 week high of LSE:TCF is £0.03 and 52 week low is £0.01.
When is next earnings date of TheraCryf PLC(LSE:TCF)?
The next earnings date of TheraCryf PLC(LSE:TCF) is 2024-10-31 Est..
Does TheraCryf PLC(LSE:TCF) pay dividends? If so, how much?
TheraCryf PLC(LSE:TCF) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |